By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.
Use of biosimilars to Avastin (bevacizumab) increased to about one-fifth of patients with non-small cell lung cancer and metastatic colorectal cancer by March 2024, according to results of a real-world evidence study presented at the 2025 annual meeting of the Academy of Managed Care Pharmacy (AMCP) this week in Houston.
The research also showed that hemorrhage was more common among patients with non-small cell lung cancer treated with the Avastin biosimilars than those treated with “originator” Avastin (6.4% vs. 4.7%) but less common in patients with metastatic colorectal cancer treated with Avastin biosimilars (9.1% vs. 9.9%).
Four Avastin biosimilars have launched, starting with Mvasi (bevacizumab-awwb) in July 2019, followed by Zirabev (bevacizumab-bvzr), Vegzelma (bevacizumab-adcd) and Alymys (bevacizumab-maly). Bevacizumab inhibits vascular endothelial growth factor (VEGF), a protein that helps spur the growth of blood vessels that supply tumors with oxygen and nutrients.
Cate Lockhart, Pharm.D., Ph.D.
Cate Lockhart, Pharm.D., Ph.D., chief science officer of AMCP and executive director at Biologics and Biosimilars Collective Intelligence Consortium, and her co-researchers used deidentified data from Carelon Research’s Healthcare Integrated Research Data from July 1, 2017, through March 31, 2024. Carelon is a research arm of Elevance Health, formerly known as Anthem, one of the largest health insurance companies in the U.S. They identified 1,307 patients with non-small cell lung cancer and metastatic colorectal cancer and 4,688 patients with metastatic colorectal cancer. Among the patients with non-small cell lung cancers, the proportion treated with Avastin biosimilars increased from 0% in 2018 to 23.9% in 2023. The pattern was similar among those with metastatic colorectal cancer, with the proportion increasing from 0% in 2018 to 21.8% in 2023. Over the same time period, the use of Avastin fell from 14.9% to 11.9% among the patients with non-small cell lung cancer, which accounts for approximately 80% of lung cancers, and from 22.9% to 7.4%.
Although adverse outcomes varied between cohorts, Lockhart and her colleagues concluded that the efficacy and safety of Avastin biosimilars were comparable to the originator and that the originator and biosimilar were used by similar patients.
Specialty Drugs Dominate Pharmaceutical Frontier in 2025
April 15th 2025In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Read More
340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More